The efficacy of fluconazole, a new bis-triazole antifungal agent, was compared with' that of orally administered ketoconazole and parenterally administered amphotericin B against aspergillus and cryptococcus infections in mice. Fluconazole was 5-20-fold more active than ketoconazole against systemic aspergillosis and against systemic, intracranial and pulmonary cryptococcosis but was less active than amphotericin B
We have compared the activities of posaconazole and other currently available antifungal agents agai...
The efficacy of ravuconazole, a new triazole antifungal agent, and the echinocandin LY-303366 were e...
D0870 is a novel azole antifungal compound. It was compared with conventional amphotericin B and itr...
Fluconazole is a novel triazole antifungal intended for oral treatment of superficial and systemic m...
The new antifungal derivative posaconazole was tested against three clinical isolates of Cryptococcu...
The new antifungal derivative posaconazole was tested against three clinical isolates of Cryptococcu...
The new antifungal derivative posaconazole was tested against three clinical isolates of Cryptococcu...
three agents have significant toxicity, and both amphoter-icin B and miconazole must be given intrav...
Forty Cryptococcus gattii strains were submitted to antifungal susceptibility testing with fluconazo...
The new antifungal derivative posaconazole was tested against three clinical isolates of Cryptococcu...
In vitro and in vivo antifungal activities of D0870 were evaluated in comparison with those of fluco...
D0870 is a recently developed triazole with characteristics of a broad spectrum of activity and slow...
Forty Cryptococcus gattii strains were submitted to antifungal susceptibility testing with fluconazo...
Viability studies showed that fluconazole (UK-49,858) was strictly fungistatic in its activity again...
Forty Cryptococcus gattii strains were submitted to antifungal susceptibility testing with fluconazo...
We have compared the activities of posaconazole and other currently available antifungal agents agai...
The efficacy of ravuconazole, a new triazole antifungal agent, and the echinocandin LY-303366 were e...
D0870 is a novel azole antifungal compound. It was compared with conventional amphotericin B and itr...
Fluconazole is a novel triazole antifungal intended for oral treatment of superficial and systemic m...
The new antifungal derivative posaconazole was tested against three clinical isolates of Cryptococcu...
The new antifungal derivative posaconazole was tested against three clinical isolates of Cryptococcu...
The new antifungal derivative posaconazole was tested against three clinical isolates of Cryptococcu...
three agents have significant toxicity, and both amphoter-icin B and miconazole must be given intrav...
Forty Cryptococcus gattii strains were submitted to antifungal susceptibility testing with fluconazo...
The new antifungal derivative posaconazole was tested against three clinical isolates of Cryptococcu...
In vitro and in vivo antifungal activities of D0870 were evaluated in comparison with those of fluco...
D0870 is a recently developed triazole with characteristics of a broad spectrum of activity and slow...
Forty Cryptococcus gattii strains were submitted to antifungal susceptibility testing with fluconazo...
Viability studies showed that fluconazole (UK-49,858) was strictly fungistatic in its activity again...
Forty Cryptococcus gattii strains were submitted to antifungal susceptibility testing with fluconazo...
We have compared the activities of posaconazole and other currently available antifungal agents agai...
The efficacy of ravuconazole, a new triazole antifungal agent, and the echinocandin LY-303366 were e...
D0870 is a novel azole antifungal compound. It was compared with conventional amphotericin B and itr...